Using sequential infusions of two S-phase-specific drugs, iododeoxyuridine and bromodeoxyuridine, we have developed an in vivo method for determining the labeling index (U), the S-phase duration (%), and total cell cycle times (Tc) of non-Hodgkin's lymphomas. In nine non-Hodgkin's lymphomas studied, the LI ranged from 1.5 YO in a follicular small cleaved-cell lymphoma to 29.6% in a diffuse large-cell lymphoma. The Ts ranged from 16 hr in a large-cell lymphoma (immunoblastic type) to 117 hr in a follicular small cleavedcell lymphoma. The Tc varied from 69 hr in a large-cell lymphoma (immunoblastic type) to over IO00 hr in all low-grade lymphomas studied. Immunohistochemical methods using anti-BrdU antibodies were used to detect cell incorporation
,ntroduction
Over the last decade, several different methods have been used in the study of cell cycle kinetics of non-Hodgkin's lymphomas. Measurement of labeling indices based on in vitro [3H]-thymidine uptake, or on DNA content as determined by flow cytometry, have been used widely (1-12). Recently, estimation of the growth fraction with the monoclonal antibody (MAb) Ki-67 (2,12,13), or calculation of labeling indices utilizing anti-BrdU monoclonal antibodies, has also been reported (12). Results from each of these methods have demonstrated prognostic significance in lymphomas (1-12). In these various reports, lymphomas with higher labeling indices were associated with high-grade histological subtypes and ultimately with a poorer prognosis.
One common feature of these studies is that all have been performed in vitro either on cell suspensions or on tissue sections. To date, in vivo studies of cell cycle kinetics in human lymphomas have * Supported in part by the Ruth Lyons Fund (Cincinnati, Ohio). * Correspondence to: Dr. Azra Raza, Director, Hematologic Oncology Program, Univ. of Cincinnati Medical Center, 231 Bethesda Ave. (ML 508) . Cincinnati, of the two S-phase-specific drugs. In this manner, cell cycle times could be calculated while the architecture of the tumor specimen was preserved. Difficulties in using this methodology, specifically in the calculation of the growth fraction and total cell cycle times, are pointed out. This in vivo method does, however, allow for Ts calculations independent of growth fraction considerations. Correlations of cell cycle data with various biological and clinical factors await further patient follow-up. (J Hisrochem Cyrochem 40: KEY WORDS: Cell cycle kinetics; Lymphomas; Non-Hodgkin's lymphomas; Bromodeoxyuridine.
723-728, 1992)
not been reported. In our present study we describe an in vivo tecl nique to calculate the labeling indices, S-phase durations, and total cell cycle times of lymphomas using two thymidine analogues, iododeoxyuridine (IUdR) and bromodeoxyuridine (BrdU). These labels have previously been used in vivo, either singly or together, in the determination of cell cycle parameters of adult leukemias (14-16), brain tumors (17), and colorectal cancers (18J9).
Materials and Methods
The IUdRlBrdU protocol (NCI #T89-0106) utilized in this study was reviewed and approved by the Institutional Review Board (IRB) of the Univcrsity of Cincinnati Medical Center, the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). The IUdR and BrdU were supplied by the NCI. Informed consent required by the local IRB, NCI, and FDA was obtained from every patient before the administration of BrdU and IUdR.
All patients involved in the study were diagnosed and treated at the University of Cincinnati Medical Center. Both newly diagnosed lymphoma patients and relapsed patients were eligible for the protocol. In all cases patients were diagnosed as having a malignant neoplasm before receiving IUdR and BrdU.
Administration of IUdR and BrdU. The two DNA labels, IUdR and BrdU, were given to patients before tumor resection or biopsy, as follows. Y M , YOUSUF, MILLER, SWERDLOW, LAMPKIN, RAZA First, IUdR (100 mglm2) was infused intravenously over 1 hr. A 1-hr rest period then followed. BrdU (100 mglm2) was next given intravenously over 1 hr. At the end of the BrdU infusion the tumors were surgically removed and a portion was fixed in Bouin's solution (picric acid, formalin, acetic acid, and water) for 3 hr, dehydrated in ethanol, and embedded in plastic using glycol methacrylate. Two-wm thin sections were then obtained, using a tungsten carbide-edged microtome, and placed on alcian blue-coated coverslips for processing.
Processing. Our processing method depends on the sequential application of two monoclonal antibodies (MAb), with immunohistochemical detection using a modification of the methods originally described by Shibui et al. (17) . and later developed by Miller et al. (20) . Our methods are based on the fact that MAb Br-3 (Caltag) recognizes only BrdU, whereas MAb 3D9 reacts with both IUdR and BrdU. Studies in our laboratory have confirmed that MAb Br-3 reacts only with BrdU, and does not crossreact with IUdR (20) . Studies on a patient that received only BrdU, and animal model studies in our laboratory have shown that MAb 3D9 does not bind to BrdU when an appropriate dilution of BR3 is applied first (unpublished data).
The tissue specimens were first rehydrated in distilled water for 10 min. They were subsequently incubated with 3% Hz02 for 30 min, Pronase (1 mglml) for 45 min. and then 4 N HCI for 20 min. The specimens were rinsed with 0.15 M PBS after each incubation. After the 4 N HCI incubation, the specimens were rinsed with 0.5 M PBS instead of 0.15 M PBS.
The specimens were then sequentially incubated with MAb Br-3 (diluted 1:3000 to 1:9000 in 0.5 M PBS with 1.5% horse serum) for 60 min, biotinylated anti-mouse IgG (diluted 1:200 in 0.5 M PBS + 1.5% horse serum) for 30 min. and ABC reagent (a mixture of avidin-DH solution and biotinylated enzyme, each diluted 1:50 with 0.5 M PBS) for 30 min. The horse serum, biotinylated anti-mouse IgG, and ABC complex were all reagents in the Vectastain Elite ABC Kit (Vector; Burlingame, CA). The samples were rinsed with 0.5 M PBS in between each of these steps. They were then stained with 0.025% 3,3'-diaminobenzidine tetrahydrochloride (diluted in 100 ml 0.5 M TBS with 0.01 ml 30% H P 2 ) for 5 min, rinsed with distilled water, and placed in 0.5 M Tris-buffered saline (TBS) for 30 min.
The second MAb, 3D9, was processed via an alkaline phosphatase-antialkaline phosphatase (APAAP) technique. MAb 3D9, diluted 1:lOO in 0.5 M TBS containing 0.25% Tween-20, was applied to the above sections for 60 min. The samples were then rinsed with 0.5 M TBS, incubated for 30 minute with a 1:20 dilution of rabbit anti-mouse IgG (Dako; Santa Barbara, CA) in 0.5 M TBS, and rinsed again with 0.5 M TBS. A 1:40 dilution of mouse alkaline phosphatase-anti-alkaline phosphatase antibody (Dako) in 0.5 M TBS was next applied for 30 min. After another 0.5 M TBS rinse, the samples were developed using a fast blue substrate solution prepared as follows. Twenty mg of naphthol AS-MX phosphate were thoroughly dissolved in 2.0 ml N,N-dimethyl formamide and added to 100 ml of 0.1 M Tris buffer (pH 8.2). To inhibit endogenous alkaline phosphatase activity, 0.1 ml of 1 M Levamisol was added to the above solution. Next, 100 mg of Fast Blue BB Salt were added, mixed well, and filtered. The samples were then immersed in the fast blue solution for an average of 15 min, rinsed in distilled water, mounted with Fluoromount, and allowed to dry overnight.
Calculation of LI, Ts, and Tc. After the above processing technique, the cells were counted under light microscopy. Several different nuclear staining patterns were seen with our technique: blue only, brown only, blue + brown, or clear. Cells that incorporated IUdR only were labeled blue by the MAb 3D9/APAAP technique. Cells that incorporated BrdU only were labeled brown by the MAb Br-3/avidin-biotin technique. Cells that contained both IUdR and BrdU were double stained both blue and brown. Cells that did not incorporate either label remained clear. To measure the percentage of cells in S-phase (labeling indices), the following formula was used: LI = BrdU only cells + double labeled cells
Total cells counted
The Ti of each specimen was calculated using the formula adapted from Wimber and Quastler (21):
IUdR only cells where t is the time interval between labels, as measured from the start of the first infusion to the start of the second infusion. The total cell cycle times for each tumor specimen were derived from LI and 15 values as follows: Tc = (LIlTs) x growth fraction (22) . For labeling indices calculations, 4000-26,000 cells were counted. For Ts calculations, a minimum of 1250 cells in S-phase (labeled cells) were counted. For Tc calculations, a growth fraction of 1.0 was used (see Discussion). All slides were read independently by two different observers. No significant differences between observers values were noted when matched t-tests were performed.
Patient population. Nine non-Hodgkin's lymphomas were studied (Eble 1). Through previous surgical biopsy or bone marrow results, all patients were diagnosed with malignant neoplasms before their IUdR and BrdU infusions. Three patients with non-Hodgkin's lymphomas (Patients 2. 7, and 8) were studied at the time of relapse. All other patients were studied at the time of initial diagnosis.
Of the nine non-Hodgkin's lymphomas, there were three follicular small cleaved-cell lymphomas, one diffuse small cleaved-cell lymphoma, one diffuse mixed small cleaved-and large-cell lymphoma, two diffuse large-cell lymphomas, one large-cell immunoblastic lymphoma, and one paraimmunoblastic variant of small lymphocytic lymphoma. The non-Hodgkin's cases were subdivided into low grade, intermediate grade (except for diffuse large cell), and diffuse large-celUlarge-cell-immuno blastic categories. Patient 6. the paraimmunoblastic variant of small lymphocytic lymphoma, immunophenotypically was B-cell in nature, and was best considered as intermediate grade in the working formulation. 
Results
Several different nuclear labeling patterns were noted in the lymphoma samples (Figure 1) . Cells that had incorporated both IUdR and BrdU were cells in S-phase during both infusions. Therefore, they exhibited both a blue and a brown nuclear label (Figure 2a ).
Cells labeled by IUdR alone were cells that had left S-phase before the start of the BrdU infusion (Figure 2b , blue nuclear label). Cells labeled by BrdU alone were cells that had entered S-phase after completion of the IUdR infusion (Figure 2c , brown nuclear label).
Differences in labeling between various histological grades of lymphomas are shown in Figure 3 . Figure 3a reveals the staining pattern in a low-grade, follicular small cleaved-cell non-Hodgkin's lymphoma. Figure 3b s h m the pattern in an intermediate grade, diffuse small cleaved-cell non-Hodgkin's lymphoma. Figure 3c reveals the staining of a diffuse large-cell lymphoma. As demonsuated in Figures 2 and 3 , the staining varied from a peripheral nuclear stain, to a diffuse nuclear stain, to a variable nucleolar staining pattern among different cells from any single tumor sample. Visually, labeling of the lymphomas did not grossly vary between the peripheral margins and the central regions of any specimen in this study. In addition, labeling near blood vessels did not vary markedly from regions distant to vessels. 
Discussion
The prognostic significance of studying labeling indices in lymphomas has already been reported by several authors (1-12) . Unlike flow cytomeuic techniques, whereby labeling indices are quickly derived on tens of thousands of cells, assessment of labeling indices with our technique is dependent on the visual counting of several thousand cells. Unlike flow cytometric methods, however, our in vivo methodology leaves the tumor architecture preserved. Therefore, the geographic orientation of S-phase cells within the tumor may be seen. Furthermore, none of the previous lymphoma studies that utilized flow cytomeuic techniques or in vitro [ 3H]-thymidine labeling were able to predict S-phase durations. Potentially, this calculation of Ts values may be the most useful application of our technique. If, for example, two lymphomas with similar labeling indices have different Ts values, could one case therefore be predicted to be more aggressive than the other? For example, compare Patient 2 with Patient 3. Although both are low-grade lymphomas with nearly identical labeling indices (4.8% vs 4.9%), the Ts for Patient 2 is less than 50% the value for Patient 3. If DNA analysis by flow cytometry or Ki-67 staining had been used in comparing these two patients, the differences in Ts durations would not have been noted. With the further accrual and follow-up of patient tumors with similar labeling indices, the clinical significance of Ts differences may yet be found. The importance of knowing Ts values has already been demonstrated in myeloid leukemias (23) . In this study of 54 patients by Raza et al., shorter Ts times correlated with shorter remission durations. Labeling indices alone did not correlate with remission durations. Myeloid leukemias with identical labeling indices, but significantly different Ts and Tc values, often showed marked differences in their course and response to therapy in this study. Similar findings may ultimately be identified in lymphomas as well.
Although our patient population is too small for performance of adequate statistical analyses, the higher-grade lymphomas in this study tended to have higher LI and lower Ts than lower-grade lymphomas ( Table 3) . The mean LI values for our non-Hodgkin's lymphomas were greater than those of Silvestrini et al. (I) , in whose experience the labeling indices of low grade lymphomas were found to have a mean value = 1.7%, intermediate grade = 4.7%, and high-grade = 14.2%. Likewise, the mean Ts value of the three largecell lymphomas in this report (21 hr & 5 hr) was greater than the Ts values (14 hr) noted by Peckham and Steel (24) and Schiffer (2 5) in two separate [3H]-thymidine trials. Finally, owing to the small number of cases studied, no definitive correlation between the Ts values and labeling indices for our non-Hodgkin's lymphomas could be seen by standard regression analysis. As further patient numbers accrue, more detailed comparisons between the T i and LI will be available.
Difficulties in our methods should be noted. As discussed earlier, total cell cycle times (Tc) can be calculated as Tc = (LUX) x growth fraction. Therefore, the calculated T c values are greatly dependent on the percentage of cells in cycle. Our use of a 100% growth fraction for the Tc calculation is clearly a gross overestimation. The vast majority of lymphomas would be expected to have growth fractions significantly less than 100%. Our methods simply did not allow for the determination of growth fraction values. The Tc values reported in Tables 2 and 3 serve to point out the difficulties one has in determining total cell cycle times without the knowledge of the growth fraction. The problem of growth fraction determination, however, is not limited to our study alone. In general, a reliable method has yet to be agreed upon that estimates the growth fraction of lymphomas. Transferrin receptor expression and Ki-67 expression have both been analyzed as possible indicators of the growth fraction in leukemias and lymphomas (2, 12, (26) (27) (28) . Although reported to represent all cells in cycle, Veneroni et al. (2) have speculated that %-67 may not be useful in differentiating GO cells from G1 cells in low-grade lymphomas. Furthermore, Schrape et al. (12) speculated that the HB21 monoclonal antibody used for studying transferrin receptors may not be a reliable indicator of proliferating lymphoma cells. Other potential methods for determining the proportion of cycling ce& in lymphomas include cycle-specific proteins such as PCNAlcyclin and P-105 (both nuclear antigens), and P-145 (a nucleolar antigen) (29) (30) (31) (32) (33) . To date, information regarding the application of PCNAl cyclin, P-145, and P-105 in lymphomas is very limited (30, 33) . Therefore, in the absence of a well agreed on method to estimate the growth fraction, the reported X values in this study must be viewed as estimations using an imperfect model (one in which each tumor cell is simply assumed to be in cycle).
Growth fraction estimations do not affect our Ti calculations, however (see above). For estimation of S-phase duration (Ts), only the positively labeled cells are examined to determine whether they contain a single or a double label in the nucleus. Unlabeled cells, which may or may not be in cycle, are not utilized at all in the Ti calculations. Therefore, as two DNA-specific probes are incorporated by the S-phase cells in vivo, our 3 calculations may potentially be a useful indicator of cell proliferation in lymphomas, independent of growth fraction values. Raza et al. (34) previously noted the dfierent labeling patterns that can be seen with this in vivo double label technique. Figure  2 again points this out. Labeling near the periphery of the nucleus, diffuse labeling of the entire nucleus, and distinct nucleolar labeling can be seen in various cells. This variability in nuclear staining patterns may be due to the fact that cells were in different stages of S-phase when the IUdR and/or BrdU were incorporated. The synthesis of heterochromatin and euchromatin is generally felt to progress through an orderly sequence of events, each specific to different nuclear regions (35, 36) . In this manner, cells in early S-phase may take up IUdR or BrdU differently from cells late in S-phase.
In summary, this report describes a novel in vivo double label technique to study the cell cycle kinetics of human lymphomas. We are excited to have successfully used this methodology to determine the S-phase durations for lymphomas on an in vivo basis. We recognize that the difficulties in determining the growth fractions of lymphomas will lead to significant problems in obtaining accurate labeling indices and total cell cycle time measurements. This problem is not inherent to our methodology alone, however. Furthermore, our in vivo methodology may ultimately enable us to study the kinetics of different regions of lymphomas. We are currently doing further work in this area. For now, our patient numbers are too few to give statistical significance to our cell cycle data. The preliminary trends, towards lower 3 durations and higher labeling indices in higher-grade lymphomas, are fascinating nevertheless.
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